Key Highlights
- Verici Dx Plc (LSE:VRCI) climbed 7.14% on 5 October 2026.
- Tutivia testing Revenue rose 53% in the first half of 2026 to $1.77 million as more US transplant centres adopted the test.
- Third-quarter 2026 orders were on track for a 53% year-on-year increase, according to the company.
- Verici Dx has proposed a further Equity fundraise to support its growth plans, following a £2.6 million raise in June 2026.
Why Is Verici Dx Plc (LSE:VRCI) in Focus Today?
Verici Dx Plc (LSE:VRCI) rose 7.14% on Monday, 5 October 2026, as investors continued to digest the company's half-year results and its plans for additional funding. The kidney transplant diagnostics specialist has reported steady growth in Demand for its Tutivia test, and the market appears to be focusing on commercial momentum rather than the dilution that comes with new equity.
No new announcement had been confirmed at the time of writing. The gain appears to reflect recovery buying after the shares traded near historic lows, combined with encouragement from rising test volumes in the US.
What Does Verici Dx Do?
Verici Dx develops advanced clinical diagnostics for organ transplantation, with a focus on kidney transplant patients. Its lead product, Tutivia, is a blood-based test designed to assess the risk of acute rejection after transplant, helping clinicians make more informed treatment decisions. The company is also developing Clarava, a pre-transplant prognostic test. Verici operates a laboratory in the United States and has an out-licensing agreement with Thermo Fisher Scientific.
Half-Year Results Show Growing Adoption
Verici Dx reported unaudited interim results for the six months ended 30 June 2026. Total revenues were $1.8 million, compared with $1.9 million a year earlier. However, the comparison is affected by licensing revenue: the prior-year period included $0.75 million from Thermo Fisher, while 2026 had none. Tutivia testing revenue, the key growth driver, rose 53% to $1.77 million from $1.16 million.
The adjusted EBITDA loss widened to $3.5 million from $2.8 million, reflecting Investment in commercial expansion. Cash stood at $2.4 million at 30 June 2026, compared with $3.3 million at the end of 2025, and net cash outflow from Operating Activities was $3.8 million. The company completed an equity fundraise in June 2026 raising gross proceeds of £2.6 million.
Verici said it was achieving an average reimbursement rate of around $2,300 per test. Testing volumes have continued to increase quarter on quarter, with the third quarter of 2026 on track for a 53% increase in orders year on year. In the first quarter of 2026, testing volumes rose 32% quarter on quarter to 392.
Reimbursement and Coverage Progress
Verici has made progress on reimbursement, which is critical for diagnostics adoption in the US. The company has received Medicare coverage for Tutivia, and the test was added as an in-network test under a Blue Cross Blue Shield arrangement. Broader payer coverage improves the likelihood that transplant centres will order the test routinely.
Proposed Fundraise
Alongside its interim results, Verici announced a proposed further equity fundraise to support its growth plans, with trading in its shares entering a Capital access window while the bookbuild was conducted. The price and size of the raise were to be determined after completion of the bookbuild. While additional funding dilutes existing shareholders, it extends the company's cash runway as it scales commercial operations.
Why Did Verici Dx Shares Rise 7.14% Today?
The following factors appear to have contributed to Monday's move:
- Testing growth: A 53% rise in Tutivia testing revenue demonstrates growing clinical adoption.
- Order momentum: Third-quarter orders on track for 53% annual growth support the outlook for the second half.
- Funding clarity: Progress on new funding reduces near-term cash concerns.
- Low base: The shares had fallen to very low levels, leaving room for a rebound as sentiment improves.
Key Risks to Consider
Verici remains loss-making and has relied on repeated equity raises, which have significantly increased the share count. Its cash position is limited relative to its burn rate. Commercial adoption of diagnostics can be slow, and reimbursement decisions by payers can affect revenue. The company faces competition from other transplant diagnostics providers.
Outlook for Verici Dx Plc (LSE:VRCI)
The 7.14% gain on 5 October 2026 reflects growing confidence in Tutivia's commercial traction. The next milestones include the completion of the proposed fundraise, a third-quarter trading update and further progress on payer coverage. If test volumes keep rising at the current pace, Verici Dx Plc (LSE:VRCI) could move closer to a sustainable commercial model, although funding needs and dilution will remain key considerations.






Please wait processing your request...